Neutralizing activity induced by the attenuated coxsackievirus B3 Sabin3-like strain against CVB3 infection

Current Microbiology

Volumn 68, Issue 4, 2014, Pages 503-509

  Jrad Battikh, Nadia ^a   Souii, Amira ^a   Oueslati, Leila ^a   Aouni, Mahjoub ^a   Hober, Didier ^b   Gharbi, Jawhar ^a,c   Ben M'Hadheb Gharbi, Manel ^c  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b UNIV LILLE   (France)

^c UNIVERSITY OF MONASTIR   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; CHILD; COXSACKIEVIRUS INFECTIONS; ENTEROVIRUS B, HUMAN; FEMALE; HUMANS; INFLAMMATION; MICE; MUTATION; MYOCARDIUM; NEUTRALIZATION TESTS; PANCREAS; VERO CELLS;

EID: 84893953973     PISSN: 03438651     EISSN: 14320991     Source Type: Journal    
DOI: 10.1007/s00284-013-0498-z     Document Type: Article

References (24)

1. Tam PE (2006) Coxsackievirus myocarditis: interplay between virus and host in the pathogenesis of heart disease. Viral Immunol 19:133-146
2. Huber SA, Born W, O'Brien R (2005) Dual functions of murine gammadelta cells in inflammation and autoimmunity in coxsackievirus B3-induced myocarditis: role of Vγ1+ and Vγ4+ cells. Microbes Infect 7:537-543
3. Bailey JM, Tapprich WE (2007) Structure of the 5′ nontranslated region of the coxsackievirus B3 genome: chemical modification and comparative sequence analysis. J Virol 81:650-668
4. Natarajan P, Johnson JE (1998) Molecular packing in virus crystals: geometry, chemistry, and biology. J Struct Biol 121:295-305
5. Fohlman J, Pauksen K, Morein B, Bjare U, Ilback NG, Friman G (1993) High yield production of an inactivated coxsackie B3 adjuvant vaccine with protective effect against experimental myocarditis. Scand J Infect Dis 88:103-108
6. Henke A, Jarasch N, Martin U, Wegert J, Wildner A, Zell R, Wutzler P (2008) Recombinant coxsackievirus vectors for prevention and therapy of virus-induced heart disease. Int J Med Microbiol 298:127-134
7. See DM, Tilles JG (1997) Occurrence of coxsackievirus hepatitis in baby rabbits and protection by a formalin inactivated polyvalent vaccine. Proc Soc Exp Biol Med 216:52-56
8. Xu W, Shen Y, Jiang Z, Wang Y, Chu Y, Xiong S (2004) Intranasal delivery of chitosan-DNA vaccine generates mucosal SIgA and anti-CVB3 protection. Vaccine 22:3603-3612
9. Godney EK, Arizpe HM, Gaunti CJ (1987) -1988). Characterization of the antibody response in vaccinated mice protected against Coxsackievirus B3-induced myocarditis. Viral Immunol 1:305-314
10. Ben M'hadheb-Gharbi M, Gharbi J, Paulous S, Brocard M, Komaromva A, Aouni M, Kean KM (2006) Effects of the Sabin-like mutations in domain V of the internal ribosome entry segment on translational efficiency of Coxsackievirus B3. Mol Gen Genomics 276:402-412
11. Huang ML, Chiang PS, Luo ST, Liou GY, Lee MS (2010) Development of a high-throughput assay for measuring serum neutralizing antibody against enterovirus 71. J Virol Methods 165:42-45
12. Park JH, Kim DS, Cho YJ, Kim YJ, Jeong SY, Lee SM, Cho SJ, Yun CW, Jo I, Nam JH (2009) Attenuation of coxsackievirus B3 by VP2 mutation and its application as a vaccine against virus-induced myocarditis and pancreatitis. Vaccine 27:1974-1983
13. Chang LY, King CC, Hsu KH, Ning HC, Tsao KC, Li CC, Huang YC, Shih SR, Chiou ST, Chen PY, Chang HJ, Lin TY (2002) Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan. Pediatrics 109:e88
14. Kung SH, Wang SF, Huang CW, Hsu CC, Liu HF, Yang JY (2007) Genetic and antigenic analyses of enterovirus 71 isolates in Taiwan during 1998-2005. Clin Microbiol Infect 13:782-787
15. Yoon JW, Austin M, Onodera T, Notkins AL (1979) Isolation of a virus from the pancreas of a child with diabetic ketoacidosis. N Engl J Med 300:1173-1179
16. World Health Organization (WHO) (1997) Manual for the virological investigation of polio. WHO, Geneva
17. Dan M, Chantler JK (2005) A genetically engineered attenuated Coxsackievirus B3 strain protects mice against lethal infection. J Virol 79:9285-9295
18. Dunn JJ, Bradrick SS, Chapman NM, Tracy SM, Romero JR (2003) The stem loop II within the 5′ nontranslated region of clinical Coxsackievirus B3 genomes determines cardiovirulence phenotype in a murine model. J Infect Dis 187:1552-1561
19. Kim JY, Jeon ES, Lim BK, Kim SM, Chung SK, Kim JM (2005) Immunogenicity of a DNA vaccine for Coxsackievirus B3 in mice: protective effects of capsid proteins against viral challenge. Vaccine 23:1672-1679
20. Reed LJ, Muench H (1938) A simple method of estimating fifty percent endpoints. Am J Hyg 27:493-497
21. Tu Z, Chapman MN, Hufnagel G, Tracy S, Romero JR, Barry WH, Zhao L, Currey K, Shapiro B (1995) The cardiovirulent phenotype of Coxsackievirus B3 is determined at a single site in the genomic 5′ nontranslated region. J Virol 69:4607-4618
22. Ben M'hadheb-Gharbi M, Kean KM, Gharbi J (2009) Molecular analysis of the role of IRES stem-loop V in replicative capacities and translation efficiencies of Coxsackievirus B3 mutants. Mol Biol Rep 36:255-262
23. Le SY, Siddiqui A, Maizel JV (1996) A commun structural core in the internal ribosome entry sites of picornavirus, hepatitis C virus and pestivirus. Virus Genes 12:135-147
24. Rinehart LO, Gomez RM, Root RP (1997) Molecular determinants for virulence in coxsackievirus B1 infection. J Virol 71:3986-3991